Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 5, 2005, Pages 233-238

  Yoshimoto, Akihiro ^a   Kasahara, Kazuo ^a   Nishio, Makoto ^b   Hourai, Takeshi ^b   Sone, Takashi ^a   Kimura, Hideharu ^a   Fujimura, Masaki ^a   Nakao, Shinji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Angiogenic growth factors; Epidermal growth factor receptor; Gefitinib; Non small cell lung cancer

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOTOXIC AGENT; GEFITINIB; GELATINASE A; GELATINASE B; GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR 2; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; VOLUNTEER; BIOSYNTHESIS; LUNG TUMOR; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; QUINAZOLINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 21744458741     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi074     Document Type: Article

References (36)

1. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1991;82:4-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenetic switch during tumorigenesis. Cell 1996;86:353-64.
3. Herbst RS, Fidler IJ. Angiogenesis and lung cancer: Potential for therapy. Clin Cancer Res 2000;6:4604-6.
4. Cox G, Jones JL, Walker RA, Stewart WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000;27:81-100.
5. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-14.
6. Tamura M, Ohta Y, Kajita T, Kimura K, Go T, Oda M, et al. Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 2001;8:1097-102.
7. Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K, et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000;118:948-51.
8. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-7.
9. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998;18:1251-4.
10. Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 1998;18:2063-8.
11. Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: Correlation with platelet and leukocyte counts. Lung Cancer 2001;33:171-9.
12. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002;35:29-34.
13. Jager R, List B, Knabbe C, Souttou B, Raulais D, Zeiler T, et al. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer 2002;86:858-63.
14. Brattström D, Bergqvist P, Hesselius A, Larsson A, Lamberg K, Wernlund J, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002;37:57-63.
15. Okada-Ban M, Thuery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:263-7.
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807.
17. Richardson CM, Sharma RA, Cox G, O'Byrne KJ. Epidermal growth factor receptor and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: Potential targets for chemoprevention and systemic therapy. Lung Cancer 2003;39:1-13.
18. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
19. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
20. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
21. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7:1459-65.
22. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-60.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
24. Gille J, Swerlick RA, Caughman SW. Transforming growth factor α-induced transcriptional activation of the vascular permeability factor (VPF/ VEGF) gene requires AP2-dependent DNA binding and transactivation. EMBO J 1997;16:750-9.
25. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001;31:213-9.
26. Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancar. Cancer Res 2002;62:5210-5217.
27. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum metalloproteinase-2, -9 and tissue inhibitors of metalloproteinase-1, -2 in lung cancer-TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311-6.
28. Iizawa T, Fujisawa T, Suzuki M, Motohashi S, Yasuhuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res 1999;5:149-53.
29. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respir Med 2001;95:1-4.
30. Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1161-9.
31. Zucker S, Lysik RM, Zarrabi MH, Stetler-Stevenson W, Liotta LA, Birkedal-Hansen H, et al. Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer. Cancer Epidemiol Biomarkers Prev 1992;1:475-9.
32. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52:4548-9.
33. Ylisirnio S, Hoyhtya M, Makitaro R, Paakko P, Risteli J, Kinnula VL, et al. Elevated serum levels of type I collagen degradation marker I CTP and tissue inhibitors of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 2001;7:1633-7.
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
35. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
36. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.